Sun Pharma Q4 profit surges 28% to ₹2,654 cr
Full fear FY24 gross sales up 10.4% YoY, EBITDA up 11.8% and adjusted net profit up 16.5%
sun pharma q4
May 2024
May 2022
Lawsuit settlements drag Sun Pharma into ₹2,227 cr loss in Q4
Sun Pharma incurred an exceptional loss of ₹3,936 crore on account of settlements, provisions related to Taro Pharmaceuticals, Ranbaxy.
